Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TDM-based piperacillin optimisation in severe sepsis or septic shock
DRKS00011159Phase 3Completed
- Sponsor
- Friedrich Schiller University Jena
- Start
- Oct 2016
- Modality
- Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of piperacillin + tazobactam in sepsis and septic shock (2 arms), sponsored by Friedrich Schiller University Jena. Primary endpoints: Organ function and Survival. Started Oct 2016; status: completed.
02
Drugs
piperacillin + tazobactam
03
Conditions
sepsisseptic shock
Beyond the preview
Go deeper on DRKS00011159.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on DRKS00011159.